[go: up one dir, main page]

MA33637B1 - Cristaux - Google Patents

Cristaux

Info

Publication number
MA33637B1
MA33637B1 MA34554A MA34554A MA33637B1 MA 33637 B1 MA33637 B1 MA 33637B1 MA 34554 A MA34554 A MA 34554A MA 34554 A MA34554 A MA 34554A MA 33637 B1 MA33637 B1 MA 33637B1
Authority
MA
Morocco
Prior art keywords
crystals
compound
diffraction
give
powder
Prior art date
Application number
MA34554A
Other languages
Arabic (ar)
English (en)
Inventor
Hideyuki Itou
Koji Nakamichi
Takashi Tosaka
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43386634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33637(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MA33637B1 publication Critical patent/MA33637B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

L'invention porte sur les nouveaux cristaux suivants de 2-{4-[n-(5,6-diphénylpyradin-2-yl)-n-isopropylamino]butyl­oxy}-n-(méthylsulfonyl)acétamide (désigné dans ce qui suit comme « composé a ») : les cristaux de forme i du composé a qui donnent un spectre de diffraction des rayons x sur poudre ayant des pics de diffraction au moins à des angles de diffraction (2?) de 9,4º, 9,8º, 17,2º et 19,4º ; les cristaux de forme ii du composé a qui donnent un spectre de diffraction des rayons x sur poudre ayant des pics de diffraction au moins à des angles de diffraction (2?) de 9,0º, 12,9º, 20,7º et 22,6º ; et les cristaux de forme iii du composé a qui donnent un spectre de diffraction des rayons x sur poudre ayant des pics de diffraction au moins à des angles de diffraction (2?) de 9,3º, 9,7º, 16,8º, 20,6º et 23,5º.
MA34554A 2009-06-26 2012-01-20 Cristaux MA33637B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009151728 2009-06-26
JP2009151729 2009-06-26
JP2009151727 2009-06-26
PCT/JP2010/060798 WO2010150865A1 (fr) 2009-06-26 2010-06-25 Cristaux

Publications (1)

Publication Number Publication Date
MA33637B1 true MA33637B1 (fr) 2012-10-01

Family

ID=43386634

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34554A MA33637B1 (fr) 2009-06-26 2012-01-20 Cristaux

Country Status (33)

Country Link
US (4) US8791122B2 (fr)
EP (3) EP3275871B1 (fr)
JP (1) JPWO2010150865A1 (fr)
KR (5) KR102705198B1 (fr)
CN (2) CN104326991A (fr)
AR (1) AR077242A1 (fr)
AU (1) AU2010263569B2 (fr)
BR (2) BRPI1015936B1 (fr)
CA (1) CA2764475C (fr)
CL (1) CL2011003264A1 (fr)
CO (1) CO6430432A2 (fr)
CY (3) CY1119788T1 (fr)
DK (2) DK3275871T3 (fr)
ES (2) ES2660007T3 (fr)
HR (2) HRP20180171T1 (fr)
HU (3) HUE048467T2 (fr)
IL (3) IL216928A (fr)
LT (3) LT2447254T (fr)
MA (1) MA33637B1 (fr)
MX (2) MX2011013471A (fr)
MY (1) MY186531A (fr)
NO (2) NO2447254T3 (fr)
NZ (1) NZ597352A (fr)
PH (2) PH12015502824A1 (fr)
PL (2) PL2447254T3 (fr)
PT (2) PT2447254T (fr)
RU (1) RU2556206C3 (fr)
SG (2) SG10201403313WA (fr)
SI (2) SI2447254T1 (fr)
SM (2) SMT201800077T1 (fr)
TW (1) TWI531565B (fr)
WO (1) WO2010150865A1 (fr)
ZA (1) ZA201109099B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2246336T (lt) * 2008-02-28 2020-08-25 Nippon Shinyaku Co., Ltd. Fibrozės inhibitorius
ES2532858T3 (es) * 2008-07-23 2015-04-01 Toray Industries, Inc. Agente terapéutico para insuficiencia renal crónica
CN106279047B (zh) 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 一种前列环素受体激动剂的制备方法
WO2016193994A1 (fr) 2015-05-29 2016-12-08 Megafine Pharma (P) Ltd. Selexipag amorphe et son procédé de préparation
WO2017029594A1 (fr) * 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Procédés de préparation de selexipag et de sa forme amorphe
EP3344607B1 (fr) 2015-09-03 2019-11-06 Teva Pharmaceuticals International GmbH Formes à l'état solide de selexipag
WO2017042731A1 (fr) 2015-09-10 2017-03-16 Lupin Limited Forme amorphe du sélexipag et dispersion solide associée
WO2017042828A2 (fr) * 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Procédé de préparation de sélexipag et intermédiaires de ce dernier
HUE071411T2 (hu) * 2015-12-02 2025-08-28 Nippon Shinyaku Co Ltd 2-{4-[N-(5,6-difenilpirazin-2-il)-N-izopropilamino]butiloxi}-N-(metilszulfonil)-acetamidot tartalmazó szilárd gyógyászati készítmény
WO2017109772A1 (fr) * 2015-12-20 2017-06-29 Mapi Pharma Ltd. Forme amorphe du sélexipag
EP3192502A1 (fr) 2016-01-15 2017-07-19 Sandoz Ag Composition pharmaceutique de selexipag
US10815204B2 (en) 2016-04-01 2020-10-27 Honour (R&D) Process for the preparation of diphenylpyrazine derivatives
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
WO2018008042A1 (fr) * 2016-07-05 2018-01-11 Maithri Drugs Private Limited Nouveau procédé de préparation de 2-{4-[(5,6-diphényl pyrazin-2-yl)(isopropyl)amino]butoxy}-n-(méthylsulfonyl)acétamide et nouveaux polymorphes associés
WO2018015974A1 (fr) 2016-07-20 2018-01-25 Mylan Laboratories Limited Formes polymorphes de sélexipag et dispersion solide amorphe de sélexipag
WO2018022704A1 (fr) * 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Forme cristalline vi de selexipag
WO2018078383A1 (fr) 2016-10-27 2018-05-03 Cipla Limited Composition pharmaceutique comprenant du selexipag amorphe
CN108069914A (zh) * 2016-11-17 2018-05-25 江苏艾立康药业股份有限公司 一种西里帕格晶型的制备方法
EP3554507A1 (fr) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Procédés et compositions de traitement de l'hypertension pulmonaire et d'autres troubles des poumons
EP3335699A1 (fr) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Formulation de sélexipag dans un système liquisolide
JOP20190204A1 (ar) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
JP2020528900A (ja) 2017-07-27 2020-10-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 体脂肪低減のためのプロスタサイクリン受容体アゴニスト
NZ762902A (en) 2017-09-28 2025-09-26 Nippon Shinyaku Co Ltd Form-ii crystal of 2-{ 4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy} acetic acid
US10407396B2 (en) 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
AR113882A1 (es) 2017-11-16 2020-06-24 Nippon Shinyaku Co Ltd Preparación de liberación controlada
CN111699175B (zh) 2018-02-07 2022-03-29 南京明德新药研发有限公司 前列环素受体受体激动剂
KR20200123447A (ko) * 2018-02-21 2020-10-29 니뽄 신야쿠 가부시키가이샤 입상 조성물, 입상 조성물의 제조 방법, 및 입상 조성물의 용출성 개선 방법
CN109125325B (zh) * 2018-09-25 2021-05-25 中国人民解放军总医院 前列环素受体激动剂的医药用途
WO2020157730A1 (fr) 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal Composition pharmaceutique à libération contrôlée de sélexipag ou son métabolite actif
EP3705115B1 (fr) 2019-03-07 2021-06-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition contenant du selexipag
JP2022532076A (ja) 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド サルコイドーシス関連肺高血圧症の治療方法
US12419887B2 (en) 2019-05-21 2025-09-23 Actelion Pharmaceuticals Ltd. Transitioning patients treated for pulmonary arterial hypertension to selexipag
WO2020249602A1 (fr) 2019-06-11 2020-12-17 Actelion Pharmaceuticals Ltd Procédés de traitement de l'hypertension artérielle pulmonaire
WO2021023271A1 (fr) * 2019-08-06 2021-02-11 南京明德新药研发有限公司 Forme cristalline d'un composé en tant qu'agoniste du récepteur de la prostacycline et son procédé de préparation
AU2020369912A1 (en) 2019-10-23 2022-04-14 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag
ES2994089T3 (en) 2019-11-29 2025-01-17 Actelion Pharmaceuticals Ltd Initial triple combination therapy with macitentan, tadalafil, and selexipag for treating pulmonary arterial hypertension
WO2021126884A1 (fr) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan pour traiter l'hypertension pulmonaire accompagnée d'une insuffisance cardiaque au moyen d'une fraction d'éjection préservée (ph-hf-pef)
WO2021152060A1 (fr) 2020-01-31 2021-08-05 Actelion Pharmaceuticals Ltd Composition de sélexipag à libération contrôlée
US20230073428A1 (en) 2020-02-03 2023-03-09 Actelion Pharmaceuticals Ltd Methods of treating and assessing pulmonary arterial hypertension with selexipag
CN112500358B (zh) * 2020-11-18 2022-03-15 江苏豪森药业集团有限公司 赛乐西帕晶型及其制备方法
WO2022106621A1 (fr) 2020-11-20 2022-05-27 Actelion Pharmaceuticals Ltd Sélexipag destiné à être utilisé par l'intermédiaire d'une administration intracôlon
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2022238375A1 (fr) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Méthodes de traitement de l'hypertension pulmonaire
EP4456897A4 (fr) 2021-12-31 2025-12-10 Tenax Therapeutics Inc Formulations orales de levosimendan pour le traitement de l'hypertension pulmonaire avec insuffisance cardiaque à fraction d'éjection préservée
WO2023131608A1 (fr) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Compositions à libération contrôlée
WO2023214059A1 (fr) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Composés de diphénylpyrazine utilisés en tant que promédicaments
WO2024017964A1 (fr) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable comprenant un dérivé de diphénylpyrazine
WO2024133620A1 (fr) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd Test de dissolution in vitro
JPWO2024142718A1 (fr) * 2022-12-27 2024-07-04
EP4393475A1 (fr) 2022-12-28 2024-07-03 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations comprenant du sélexipag
EP4393476A1 (fr) * 2022-12-28 2024-07-03 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulation de comprimé comprenant du sélexipag
EP4616904A3 (fr) 2022-12-28 2025-10-29 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Formulation comprenant du sélexipag
WO2024194449A1 (fr) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Composition pharmaceutique comprenant un dérivé de diphénylpyrazine
WO2025196095A1 (fr) 2024-03-20 2025-09-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable pour le traitement de l'hypertension pulmonaire

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3743289B2 (ja) 1999-05-10 2006-02-08 東レ株式会社 腎不全治療薬
US20030092760A1 (en) 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
ATE260281T1 (de) 2000-08-03 2004-03-15 Pfizer Prod Inc Diazacyclooctanverbindungen und ihre therapeutische verwendung
JPWO2002085412A1 (ja) * 2001-04-18 2004-08-05 藤沢薬品工業株式会社 組織線維化抑制剤
TWI316055B (fr) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2005000316A1 (fr) 2003-06-25 2005-01-06 Cardiovascular Institute, Ltd. Preparation a usage externe permettant d'ameliorer la fonction coitale
US7112393B2 (en) 2003-07-29 2006-09-26 Canon Kabushiki Kaisha Non-magnetic toner
LT2246336T (lt) 2008-02-28 2020-08-25 Nippon Shinyaku Co., Ltd. Fibrozės inhibitorius
WO2009154246A1 (fr) 2008-06-19 2009-12-23 日本新薬株式会社 Agent thérapeutique pour un dysfonctionnement érectile
HRP20170030T1 (hr) 2008-06-23 2017-03-24 Nippon Shinyaku Co., Ltd. Sredstvo za terapiju upalne bolesti crijeva
WO2009157397A1 (fr) 2008-06-23 2009-12-30 日本新薬株式会社 Agent thérapeutique pour une lésion au tractus intestinal accompagnant l’administration d’un anti-inflammatoire nonstéroïdien
WO2009157396A1 (fr) 2008-06-23 2009-12-30 日本新薬株式会社 Agent thérapeutique pour la sténose du canal spinal
ES2532858T3 (es) 2008-07-23 2015-04-01 Toray Industries, Inc. Agente terapéutico para insuficiencia renal crónica
EP2343292B1 (fr) 2008-09-10 2014-08-06 Asahi Glass Company, Limited Nouveau dérivé de prostaglandine i2

Also Published As

Publication number Publication date
EP3275871B1 (fr) 2020-01-15
AU2010263569B2 (en) 2016-08-18
IL216928A0 (en) 2012-02-29
US20140148469A1 (en) 2014-05-29
PT3275871T (pt) 2020-04-21
MX346318B (es) 2017-03-15
PL2447254T3 (pl) 2018-05-30
ES2797124T3 (es) 2020-12-01
CN104326991A (zh) 2015-02-04
TW201111352A (en) 2011-04-01
RU2556206C2 (ru) 2015-07-10
ES2660007T3 (es) 2018-03-20
CY1119788T1 (el) 2018-06-27
KR20240090717A (ko) 2024-06-21
KR20240090716A (ko) 2024-06-21
PL3275871T3 (pl) 2020-07-27
KR20120109457A (ko) 2012-10-08
IL243293A0 (en) 2016-02-29
CY2018011I2 (el) 2018-09-05
EP3275871A1 (fr) 2018-01-31
EP2447254B1 (fr) 2017-12-06
CY2018011I1 (el) 2018-09-05
US9340516B2 (en) 2016-05-17
KR102705198B1 (ko) 2024-09-11
HUS1800015I1 (hu) 2018-05-28
SMT201800077T1 (it) 2018-03-08
CN102459198A (zh) 2012-05-16
JPWO2010150865A1 (ja) 2012-12-10
CN102459198B (zh) 2014-09-24
RU2012102678A (ru) 2013-08-10
LTC2447254I2 (lt) 2022-04-25
SG10201403313WA (en) 2014-10-30
DK3275871T3 (da) 2020-04-06
LT2447254T (lt) 2018-01-10
HRP20200539T1 (hr) 2020-07-10
BR122021005510B1 (pt) 2022-01-11
KR102829415B1 (ko) 2025-07-03
MY186531A (en) 2021-07-25
NO2018015I1 (no) 2018-04-23
IL243287A0 (en) 2016-02-29
PT2447254T (pt) 2018-01-04
KR20250107951A (ko) 2025-07-14
PH12015502824A1 (en) 2017-05-29
MX2011013471A (es) 2012-01-30
US9440931B2 (en) 2016-09-13
EP2447254A1 (fr) 2012-05-02
EP2447254A4 (fr) 2012-12-19
HRP20180171T1 (hr) 2018-03-09
HUE048467T2 (hu) 2020-07-28
ZA201109099B (en) 2012-08-29
BRPI1015936B1 (pt) 2021-07-13
CA2764475C (fr) 2017-04-25
US20140155414A1 (en) 2014-06-05
RU2556206C3 (ru) 2021-06-15
CL2011003264A1 (es) 2012-07-06
US20150266830A1 (en) 2015-09-24
US9284280B2 (en) 2016-03-15
HK1244788A1 (en) 2018-08-17
CA2764475A1 (fr) 2010-12-29
SG176915A1 (en) 2012-01-30
AU2010263569A1 (en) 2012-02-02
LT3275871T (lt) 2020-05-11
SI3275871T1 (sl) 2020-06-30
EP3689855A1 (fr) 2020-08-05
US20120101276A1 (en) 2012-04-26
SI2447254T1 (en) 2018-03-30
CY1122893T1 (el) 2021-05-05
DK2447254T3 (en) 2018-01-15
IL243287B (en) 2021-04-29
BRPI1015936A2 (pt) 2016-08-16
WO2010150865A1 (fr) 2010-12-29
CO6430432A2 (es) 2012-04-30
HUE036721T2 (hu) 2018-07-30
SMT202000177T1 (it) 2020-05-08
NZ597352A (en) 2013-01-25
US8791122C1 (fr) 2014-07-29
AR077242A1 (es) 2011-08-10
LTPA2018008I1 (lt) 2018-05-10
KR20170024165A (ko) 2017-03-06
PH12015502825B1 (en) 2017-12-11
KR102669213B1 (ko) 2024-05-28
TWI531565B (zh) 2016-05-01
US8791122B2 (en) 2014-07-29
NO2447254T3 (fr) 2018-05-05
PH12015502825A1 (en) 2017-12-11
IL216928A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
MA33637B1 (fr) Cristaux
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
EA201290397A1 (ru) 1,3,4-оксадиазол-2-карбоксамидное соединение
EP2003954A4 (fr) Tête d'extrudeuse multiligne monomoteur
EA201000050A1 (ru) Замещенные бициклолактамные соединения
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
JP2010526777A5 (fr)
EP2203402A4 (fr) Procédés de synthèse d'oléfines fluorées
EP1999317A4 (fr) Ensemble d'usure
FR2912742B1 (fr) Procede de synthese d'acrylonitrile a partir de glycerol
WO2007147122A3 (fr) Anticorps monoclonaux qui reconnaissent sélectivement des composés de méthamphétamine et de type méthamphétamine
PT2197883E (pt) Derivados de catecolamina úteis para o tratamento da doença de parkinson
WO2009073148A3 (fr) Polymorphes de n-malonyl-bis(n'-méthyl-n'-thiobenzoylhydrazide)
EP2367949A4 (fr) Production d'alcools à chaîne ramifiée par des micro-organismes photosynthétiques
EP2141154A4 (fr) Dérivé d'oxazolidinone ayant une activité inhibitrice sur la 11 -hydroxystéroïde déshydrogénase de type i
ECSP10010499A (es) Proceso para la preparación de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida
EP2173364A4 (fr) Traitement ou prévention d'une infection par un rotavirus
BRPI0716359A2 (pt) "remoÇço do cianeto de hidrogÊnico do gÁs de sÍntese
FR2913969B1 (fr) Ecretement des pics d'impurete
ZA201000394B (en) Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
FR2905600B1 (fr) Traitement des vertiges par l'acetyl-l-leucine.
EP1813596A4 (fr) Procédé de synthèse d'une alpha, alpha-difluoroamine
DK1853241T3 (da) Anvendelse af 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandion ved behandling af Parkinson's sygdom
FR2901272B1 (fr) Procede perfectionne de fabrication de (meth)acrylates d'alkyle en c1-c4
ITMI20040230A1 (it) Composti ad attivita' antitumorale